Anti-Granzyme K 抗体 [GM-24C3] (ab3771)
Key features and details
- Mouse monoclonal [GM-24C3] to Granzyme K
- Reacts with: Human
- Isotype: IgG2b
製品の概要
-
製品名
Anti-Granzyme K antibody [GM-24C3] -
製品の詳細
Mouse monoclonal [GM-24C3] to Granzyme K -
由来種
Mouse -
特異性
This antibody recognises Granzyme K transiently expressed on the cell surface of transfected BOSC cells as well as the native protein in peripheral blood mononuclear cells. It does not cross react with Granzyme A. Specificity is routinely tested by flow cytometry on BOSC cells transiently transfected with a Granzyme K expression vector. -
種交差性
交差種: Human -
免疫原
Human Granzyme K cDNA (see relevance text).
-
特記事項
Granzymes are exogenous serine proteases that are stored in the cytotoxic granules of activated T cells and NK cells. Upon target cell contact, the contents of these granules are directionally exocytosed and, with the assistance of perforin, the granzymes enter the cytosol of the target cell. To date, five human granzymes (A, B, H, K,M) have been described at the molecular genetic level. Human granzyme K (GZMK) is a 28 kD aserine protease whose gene is located on chromosome 5q11-12 close to the granzyme A-encoding gene. Like granzyme A, it has a trypsin-like specifity cleaving at the basic residues arginine and lysine. To which extent human granzyme K plays a role in the induction of apoptosis in the target cells remains to be evaluated. However, granzyme K purified from a rat large granular lymphoma cell line (RNK-16)has been shown to induce apoptosis in vitro. High mRNA levels of granzyme K are detected inactivated T cells and NK cells but are absent in normal tissues that do not contain high numbers of these cells. Antibodies produced from cDNA: Conventional technologies usually either generate antibodies against purified proteins, or against synthetic peptides based on amino acid sequences derived from DNA sequence data. Genetic immunization involves introducing the gene in the form of a cDNA directly into an animal which translates this cDNA into protein thus stimulating an immune response against the foreign protein. Although the synthetic peptide approach is comparable in speed, the quality of antibodies generated by genetic immunization is far superior. This is because the protein is made by the immunized animal, utilzing complex cellular mechanisms that allow it to gain a native conformation. Antibodies are then generated against a native protein, such as is found in the blood or tissues of its host species. Membrane-bound or secreted proteins often create problems for conventional antibody technology because in their native form, they are often modified by glycosylation, or in some cases exist as multiple membrane-spanning proteins that are not soluble following isolation or synthesis in recombinant systems. All of these problems are avoided if the immunized animal makes the protein itself. Antibodies generated by genetic immunization have been shown to have binding affinities to the protein in the sub-nanomolar range, which are approximately 100x higher than conventionally developed antibodies and much higher than single chain antibodies. Results confirm published data for much higher avidity of sera generated by genetic immunization as compared with that gained by immunization with a corresponding recombinant protein.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles. -
バッファー
pH: 7.20
Constituent: PBS -
Concentration information loading...
-
精製度
Protein G purified -
一次抗体 備考
Granzymes are exogenous serine proteases that are stored in the cytotoxic granules of activated T cells and NK cells. Upon target cell contact, the contents of these granules are directionally exocytosed and, with the assistance of perforin, the granzymes enter the cytosol of the target cell. To date, five human granzymes (A, B, H, K,M) have been described at the molecular genetic level. Human granzyme K (GZMK) is a 28 kD aserine protease whose gene is located on chromosome 5q11-12 close to the granzyme A-encoding gene. Like granzyme A, it has a trypsin-like specifity cleaving at the basic residues arginine and lysine. To which extent human granzyme K plays a role in the induction of apoptosis in the target cells remains to be evaluated. However, granzyme K purified from a rat large granular lymphoma cell line (RNK-16)has been shown to induce apoptosis in vitro. High mRNA levels of granzyme K are detected inactivated T cells and NK cells but are absent in normal tissues that do not contain high numbers of these cells. Antibodies produced from cDNA: Conventional technologies usually either generate antibodies against purified proteins, or against synthetic peptides based on amino acid sequences derived from DNA sequence data. Genetic immunization involves introducing the gene in the form of a cDNA directly into an animal which translates this cDNA into protein thus stimulating an immune response against the foreign protein. Although the synthetic peptide approach is comparable in speed, the quality of antibodies generated by genetic immunization is far superior. This is because the protein is made by the immunized animal, utilzing complex cellular mechanisms that allow it to gain a native conformation. Antibodies are then generated against a native protein, such as is found in the blood or tissues of its host species. Membrane-bound or secreted proteins often create problems for conventional antibody technology because in their native form, they are often modified by glycosylation, or in some cases exist as multiple membrane-spanning proteins that are not soluble following isolation or synthesis in recombinant systems. All of these problems are avoided if the immunized animal makes the protein itself. Antibodies generated by genetic immunization have been shown to have binding affinities to the protein in the sub-nanomolar range, which are approximately 100x higher than conventionally developed antibodies and much higher than single chain antibodies. Results confirm published data for much higher avidity of sera generated by genetic immunization as compared with that gained by immunization with a corresponding recombinant protein. -
ポリ/モノ
モノクローナル -
クローン名
GM-24C3 -
アイソタイプ
IgG2b -
研究分野
関連製品
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
ターゲット情報
-
組織特異性
Expressed in lung, spleen, thymus and peripheral blood leukocytes. -
配列類似性
Belongs to the peptidase S1 family. Granzyme subfamily.
Contains 1 peptidase S1 domain. -
細胞内局在
Secreted. Cytoplasmic granule. - Information by UniProt
-
参照データベース
- Entrez Gene: 3003 Human
- Omim: 600784 Human
- SwissProt: P49863 Human
- Unigene: 277937 Human
-
別名
- Fragmentin 3 antibody
- Fragmentin-3 antibody
- Fragmentin3 antibody
see all
データシートおよび資料
参考文献 (0)
ab3771 は論文での使用が確認できていません。